Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Autologous cytokine-induced killer cells(Tianjin Medical University Cancer Institute and Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Autologous cytokine-induced killer cells(Tianjin Medical University Cancer Institute and Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers
9 min read
GNP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
GNP: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Liquid Tumor-infiltrating Lymphocytes(Tianjin Medical University Cancer Institute and Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Liquid Tumor-infiltrating Lymphocytes(Tianjin Medical University Cancer Institute and Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers cl
9 min read
ALV-100 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ALV-100: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
LDS Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
LDS: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Allogeneic umbilical cord-derived human mesenchymal stromal cells(Ottawa Hospital Research Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Allogeneic umbilical cord-derived human mesenchymal stromal cells(Ottawa Hospital Research Institute): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review cov
9 min read
Anti-MUC1 monoclonal antibody (AltaRex) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Anti-MUC1 monoclonal antibody (AltaRex): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position
9 min read
Recombinant Human Parathyroid Hormone (1-34), Shanghai Celgen Biopharmaceuticals(Shanghai Celgen Bio-pharmaceutical Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant Human Parathyroid Hormone (1-34), Shanghai Celgen Biopharmaceuticals(Shanghai Celgen Bio-pharmaceutical Co., Ltd.): Phase 2. 2026 diligence verdict: HOLD / OP
9 min read
PGN-EDO51 in Muscular Dystrophy, Duchenne: NCT06079736 Clinical Landscape Report 2026
18 September 2026
NCT06079736 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JWK-007 in Muscular Dystrophy, Duchenne: NCT06114056 Clinical Landscape Report 2026
18 September 2026
NCT06114056 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGT-003 in Tabes Dorsalis: NCT06138639 Clinical Landscape Report 2026
18 September 2026
NCT06138639 clinical landscape for Tabes Dorsalis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imlifidase in Muscular Dystrophy, Duchenne: NCT06241950 Clinical Landscape Report 2026
18 September 2026
NCT06241950 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.